Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma.

Rizk EM, Seffens AM, Trager MH, Moore MR, Geskin LJ, Gartrell-Corrado RD, Wong W, Saenger YM.

Am J Clin Dermatol. 2019 Oct 10. doi: 10.1007/s40257-019-00475-1. [Epub ahead of print]

PMID:
31602560
2.

Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules.

Mokrane FZ, Lu L, Vavasseur A, Otal P, Peron JM, Luk L, Yang H, Ammari S, Saenger Y, Rousseau H, Zhao B, Schwartz LH, Dercle L.

Eur Radiol. 2019 Aug 23. doi: 10.1007/s00330-019-06347-w. [Epub ahead of print]

PMID:
31444598
3.

Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.

Newton JM, Hanoteau A, Liu HC, Gaspero A, Parikh F, Gartrell-Corrado RD, Hart TD, Laoui D, Van Ginderachter JA, Dharmaraj N, Spanos WC, Saenger Y, Young S, Sikora AG.

J Immunother Cancer. 2019 Aug 13;7(1):216. doi: 10.1186/s40425-019-0698-6.

4.

Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.

Seban RD, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S, Moya-Plana A, Mokrane FZ, Gartrell RD, Finkel G, Barker L, Bigorgne AE, Schwartz LH, Saenger Y, Robert C, Dercle L.

Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2298-2310. doi: 10.1007/s00259-019-04411-7. Epub 2019 Jul 25.

PMID:
31346755
5.

Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.

Nat Med. 2019 Jun;25(6):1022. doi: 10.1038/s41591-019-0449-8.

PMID:
30996326
6.

Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.

Rizk EM, Gartrell RD, Barker LW, Esancy CL, Finkel GG, Bordbar DD, Saenger YM.

Hematol Oncol Clin North Am. 2019 Apr;33(2):291-299. doi: 10.1016/j.hoc.2018.12.005. Epub 2019 Jan 17. Review.

PMID:
30833001
7.

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.

Nat Med. 2019 Mar;25(3):462-469. doi: 10.1038/s41591-019-0349-y. Epub 2019 Feb 11. Erratum in: Nat Med. 2019 Apr 17;:.

PMID:
30742119
8.

Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.

Gartrell RD, Marks DK, Rizk EM, Bogardus M, Gérard CL, Barker LW, Fu Y, Esancy CL, Li G, Ji J, Rui S, Ernstoff MS, Taback B, Pabla S, Chang R, Lee SJ, Krolewski JJ, Morrison C, Horst BA, Saenger YM.

Clin Cancer Res. 2019 Apr 15;25(8):2494-2502. doi: 10.1158/1078-0432.CCR-18-2847. Epub 2019 Jan 15.

PMID:
30647081
9.

Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.

Hanoteau A, Newton JM, Krupar R, Huang C, Liu HC, Gaspero A, Gartrell RD, Saenger YM, Hart TD, Santegoets SJ, Laoui D, Spanos C, Parikh F, Jayaraman P, Zhang B, Van der Burg SH, Van Ginderachter JA, Melief CJM, Sikora AG.

J Immunother Cancer. 2019 Jan 15;7(1):10. doi: 10.1186/s40425-018-0485-9.

10.

Correction to: The Role of Oncolytic Viruses in the Treatment of Melanoma.

Bayan CY, Lopez AT, Gartrell RD, Komatsubara KM, Bogardus M, Rao N, Chen C, Hart TD, Enzler T, Rizk EM, Pradhan JS, Marks DK, Geskin LJ, Saenger YM.

Curr Oncol Rep. 2018 Nov 13;20(12):100. doi: 10.1007/s11912-018-0749-z.

PMID:
30426304
11.

The Role of Oncolytic Viruses in the Treatment of Melanoma.

Bayan CY, Lopez AT, Gartrell RD, Komatsubara KM, Bogardus M, Rao N, Chen C, Hart TD, Enzler T, Rizk EM, Pradhan JS, Marks DK, Geskin LJ, Saenger YM.

Curr Oncol Rep. 2018 Aug 25;20(10):80. doi: 10.1007/s11912-018-0729-3. Review. Erratum in: Curr Oncol Rep. 2018 Nov 13;20(12):100.

12.

IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy.

Chen JC, Perez-Lorenzo R, Saenger YM, Drake CG, Christiano AM.

Cell Syst. 2018 Jul 25;7(1):92-103.e4. doi: 10.1016/j.cels.2018.05.020. Epub 2018 Jun 27.

13.

Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.

Kyi C, Roudko V, Sabado R, Saenger Y, Loging W, Mandeli J, Thin TH, Lehrer D, Donovan M, Posner M, Misiukiewicz K, Greenbaum B, Salazar A, Friedlander P, Bhardwaj N.

Clin Cancer Res. 2018 Oct 15;24(20):4937-4948. doi: 10.1158/1078-0432.CCR-17-1866. Epub 2018 Jun 27.

14.

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.

Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS.

J Immunother Cancer. 2018 May 9;6(1):32. doi: 10.1186/s40425-018-0344-8.

15.

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.

Blake Z, Marks DK, Gartrell RD, Hart T, Horton P, Cheng SK, Taback B, Horst BA, Saenger YM.

J Immunother Cancer. 2018 Apr 6;6(1):25. doi: 10.1186/s40425-018-0338-6.

16.

Quantitative Analysis of Immune Infiltrates in Primary Melanoma.

Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, Blake Z, Lu Y, Askin KN, Monod A, Esancy CL, Stack EC, Jia DT, Armenta PM, Fu Y, Izaki D, Taback B, Rabadan R, Kaufman HL, Drake CG, Horst BA, Saenger YM.

Cancer Immunol Res. 2018 Apr;6(4):481-493. doi: 10.1158/2326-6066.CIR-17-0360. Epub 2018 Feb 21.

17.

Quality Assessment of Stereotactic Radiosurgery of a Melanoma Brain Metastases Model Using a Mouselike Phantom and the Small Animal Radiation Research Platform.

Wu CC, Chaudhary KR, Na YH, Welch D, Black PJ, Sonabend AM, Canoll P, Saenger YM, Wang TJC, Wuu CS, Hei TK, Cheng SK.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):191-201. doi: 10.1016/j.ijrobp.2017.05.016. Epub 2017 May 19.

18.

Current and Emerging Therapies in Metastatic Pancreatic Cancer.

Manji GA, Olive KP, Saenger YM, Oberstein P.

Clin Cancer Res. 2017 Apr 1;23(7):1670-1678. doi: 10.1158/1078-0432.CCR-16-2319. Review.

19.

Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.

Grigg C, Blake Z, Gartrell R, Sacher A, Taback B, Saenger Y.

Semin Oncol. 2016 Dec;43(6):638-646. doi: 10.1053/j.seminoncol.2016.10.005. Epub 2016 Oct 27. Review.

PMID:
28061981
20.

Introducing cancer convergence.

Blagoev KB, Ting DT, Levine H, Saenger Y, Tlsty TD, Sun B.

Cancer Converg. 2017;1(1):3. doi: 10.1186/s41236-017-0003-x. Epub 2017 Nov 1. No abstract available.

21.

Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid.

Beck KM, Dong J, Geskin LJ, Beltrani VP, Phelps RG, Carvajal RD, Schwartz G, Saenger YM, Gartrell RD.

J Immunother Cancer. 2016 Apr 19;4:20. doi: 10.1186/s40425-016-0123-3. eCollection 2016.

22.

Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.

de Moll EH, Fu Y, Qian Y, Perkins SH, Wieder S, Gnjatic S, Remark R, Bernardo SG, Moskalenko M, Yao J, Ferringer T, Chang R, Chipuk J, Horst BA, Birge MB, Phelps RG, Saenger YM.

Cancer Immunol Immunother. 2015 Sep;64(9):1193-203. doi: 10.1007/s00262-015-1726-0. Epub 2015 Jun 16.

23.

Transcriptional profiling of whole blood: a rich source of immune biomarkers in cancer.

Saenger Y, de Moll E, Fu Y.

Oncoimmunology. 2014 Jul 3;3(7):e944056. eCollection 2014.

24.

Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.

Moskalenko M, Pan M, Fu Y, de Moll EH, Hashimoto D, Mortha A, Leboeuf M, Jayaraman P, Bernardo S, Sikora AG, Wolchok J, Bhardwaj N, Merad M, Saenger Y.

Cancer Immunol Res. 2015 Mar;3(3):296-304. doi: 10.1158/2326-6066.CIR-14-0120. Epub 2015 Jan 19.

25.

Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses.

Godefroy E, Gallois A, Idoyaga J, Merad M, Tung N, Monu N, Saenger Y, Fu Y, Ravindran R, Pulendran B, Jotereau F, Trombetta S, Bhardwaj N.

Cell Rep. 2014 Dec 11;9(5):1856-1870. doi: 10.1016/j.celrep.2014.10.067. Epub 2014 Nov 26.

26.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2014 Oct 28;12:277. doi: 10.1186/s12967-014-0277-z.

27.

Blood mRNA expression profiling predicts survival in patients treated with tremelimumab.

Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K, Fisher D, Kirkwood J, Oh WK, Friedlander P.

Clin Cancer Res. 2014 Jun 15;20(12):3310-8. doi: 10.1158/1078-0432.CCR-13-2906. Epub 2014 Apr 10.

28.

Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.

Harcharik S, Bernardo S, Moskalenko M, Pan M, Sivendran M, Bell H, Hall LD, Castillo-Martín M, Fox K, Cordon-Cardo C, Chang R, Sivendran S, Phelps RG, Saenger Y.

J Am Acad Dermatol. 2014 Jun;70(6):1036-44. doi: 10.1016/j.jaad.2014.01.914. Epub 2014 Mar 31.

PMID:
24698703
29.

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong TD, Jaffee EM.

Gastroenterology. 2014 Jun;146(7):1784-94.e6. doi: 10.1053/j.gastro.2014.02.055. Epub 2014 Mar 6.

30.

Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease.

Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK, Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh WK, Palucka K, Merad M, Schadt EE, Saenger YM.

J Invest Dermatol. 2014 Aug;134(8):2202-2211. doi: 10.1038/jid.2014.85. Epub 2014 Feb 12.

31.

Oncolytic virus therapy for cancer.

Goldufsky J, Sivendran S, Harcharik S, Pan M, Bernardo S, Stern RH, Friedlander P, Ruby CE, Saenger Y, Kaufman HL.

Oncolytic Virother. 2013 Sep 23;2:31-46. doi: 10.2147/OV.S38901. eCollection 2013. Review.

32.

Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma.

Bernardo SG, Moskalenko M, Pan M, Shah S, Sidhu HK, Sicular S, Harcharik S, Chang R, Friedlander P, Saenger YM.

Melanoma Res. 2013 Feb;23(1):47-54. doi: 10.1097/CMR.0b013e32835c7e68.

PMID:
23262440
33.

Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation.

Hashimoto D, Chow A, Greter M, Saenger Y, Kwan WH, Leboeuf M, Ginhoux F, Ochando JC, Kunisaki Y, van Rooijen N, Liu C, Teshima T, Heeger PS, Stanley ER, Frenette PS, Merad M.

J Exp Med. 2011 May 9;208(5):1069-82. doi: 10.1084/jem.20101709. Epub 2011 May 2.

34.

Melanoma immunotherapy.

Sivendran S, Glodny B, Pan M, Merad M, Saenger Y.

Mt Sinai J Med. 2010 Nov-Dec;77(6):620-42. doi: 10.1002/msj.20215. Review.

PMID:
21105125
35.

Herpes simplex virus oncolytic vaccine therapy in melanoma.

Sivendran S, Pan M, Kaufman HL, Saenger Y.

Expert Opin Biol Ther. 2010 Jul;10(7):1145-53. doi: 10.1517/14712598.2010.495383. Review.

PMID:
20515292
36.

Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.

Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, Terzulli SL, Merghoub T, Houghton AN, Wolchok JD.

Cancer Res. 2008 Dec 1;68(23):9884-91. doi: 10.1158/0008-5472.CAN-08-2233.

37.

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

Wolchok JD, Saenger Y.

Oncologist. 2008;13 Suppl 4:2-9. doi: 10.1634/theoncologist.13-S4-2. Review.

38.
39.

Perceiving the avidity of T cell activation can be translated into peripheral T cell regulation.

Chen W, Zhang L, Liang B, Saenger Y, Li J, Chess L, Jiang H.

Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20472-7. Epub 2007 Dec 11.

40.

Current topics in melanoma.

Wolchok JD, Saenger YM.

Curr Opin Oncol. 2007 Mar;19(2):116-20. Review.

PMID:
17272983
41.

Cytokines in cytotherapy.

Saenger Y, Wolchok J.

Cytotherapy. 2006;8(4):313-4. No abstract available.

PMID:
16923605

Supplemental Content

Loading ...
Support Center